Rodman & Renshaw Maintains Market Perform on Cell Therapeutics

Rodman & Renshaw is out with its report today on Cell Therapeutics CTIC, maintaining Market Perform. In a note to clients, Rodman & Renshaw writes, "We are maintaining our Market Perform / Speculative Risk rating for Cell Therapeutics. The recent meeting with the FDA and presentations at ASCO highlight significant value drivers for the company. Importantly, we believe that the potential to resubmit the pixantrone NDA after satisfactorily addressing the decision to stop the study early and after conducting another independent radiologic review could result in accelerated approval by 1H12." At the time of posting, shares of CTIC were trading pre-market at $1.99, down 4.02% from Tuesday's close.